Innovation Pharmaceuticals Inc (IPIX)

[Waverunner1]

Carbapenem resistant bugs(Enterobacter)in the news recently are gm negative. Brilacidin likely has little or no activity against this bug, and the other CTIX drugs that might be relevant are far far away from clinical use.

Leo has said he was hoping the gram negative version would be ready for the Rio Olympics. That is very aggressive, but I don't think 2 years is out of the question if the need is urgent.

Even if Brilacidin is great, disappointing trial results with Kevetrin would have to lower share price.

Brilacidin on its own (and the defensin mimetics platform in general) can power the stock much higher from here. I take it you have seen the deal for Cubist?